Eli Casdin, a director of CM Life Sciences III Inc., recently acquired 48,187,043 shares of the company. The buys took place at prices ranging from $0.00 to $10.00 per share, on December 17, 2021. Casdin now owns 56,846,415 shares of the company. Casdin operates out of New York, NY. Some additional info was provided as follows:
In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences III Inc. or "CMLS III") and EQRx, Inc. ("EQRx"), among other things, (i) the Reporting Person forfeited 4,840,628 shares of CMLS III Class B common stock and (ii) each remaining share of CMLS III's Class B common stock converted pursuant to the terms of such stock into share s of the Issuer's Class A Common Stock on a one-for-one basis as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-253475).
The securities are held of record by CMLS Holdings III LLC ("CMLS Holdings III"). CMLS Holdings III is the record holder of the Class A common stock and the Class A Common Stock issuable upon the exercise of warrants reported herein. Mr. Casdin is a member of the Board of Managers of CMLS Holdings III and as a result shares voting and investment discretion with respect to the Class A common stock held of record by CMLS Holdings III. Mr. Casdin disclaims beneficial ownership of these shares except to the extent of his respective pecuniary interest therein.
The securities may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, L.P. ("CPMF"), (Casdin Venture Opportunities Fund, L.P. ("CVOF") and Casdin Private Growth Equity Fund GP, LLC. ("CPGEF" and together with CPMF and CVOF, the "Casdin Funds") (ii) Casdin Partners GP, LLC, the general partner of CPMF, (iii) Casdin Venture Opportunities Fund GP, LLC, the general partner to CVOF, (iv) Casdin Private Growth Equity Funds GP, LLC, the general partner of CPGEF and (v) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. The shares held by Casdin Partners GP, LLC may be deemed to be indirectly beneficially owned by (i) Eli Casdin, the managing member of Casdin Partners GP, LLC. The address for the Casdin entities noted herein is 1350 Avenue of the Americas, Suite 2600, New York, New York 10019. Mr. Casdin disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.)
Following the completion of the Business Combination, warrants to purchase Class A Common Stock become exercisable on April 9, 2022.
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever CM Life Sciences III Inc. makes a similar move, sign up!